Assessment of erythrocyte phospholipid fatty acid composition as a biomarker for dietary MUFA, PUFA or saturated fatty acid intake in a controlled cross-over intervention trial

Sally D Poppitt*1,2,3, Paul Kilmartin4, Paul Butler4 and Geraldine F Keogh1,2

Address: 1Human Nutrition Unit, University of Auckland, Auckland, New Zealand, 2School of Biological Sciences, University of Auckland, Auckland, New Zealand, 3Department of Medicine, University of Auckland, Auckland, New Zealand and 4Department of Chemistry, University of Auckland, Auckland, New Zealand

Email: Sally D Poppitt* - s.poppitt@auckland.ac.nz; Paul Kilmartin - p.kilmartin@auckland.ac.nz; Paul Butler - p.butler@auckland.ac.nz; Geraldine F Keogh - gfk@ctu.mrc.ac.uk

* Corresponding author

Abstract

Background: Dietary intervention trials rely on self-reported measures of intake for assessment of energy and macronutrient composition. Dietary fat intake is of particular interest due to strong associations with pathophysiology. In epidemiological trials phospholipid fatty acid composition may reflect composition of habitual diet, although strong correlations have been identified only for essential polyunsaturated fatty acids (PUFAs). Preliminary evidence shows that saturated fatty acids (SFA) C15:0 and C17:0 may be acceptable biomarkers. This study measured changes in erythrocyte membrane fatty acids during a period of strictly controlled fat feeding to investigate their use as a short-term marker of compliance, particularly for intake of SFAs.

Results: This was a randomised cross-over trial in which diet was provided and strictly controlled. 20 healthy, male subjects were given a 40 energy % (en%) fat diet, high in saturated (high-SFA, 20 en%) or unsaturated (high-USFA, 24 en%) fatty acids for 2 periods of 3 weeks. Subjects were residential during intervention with all food and beverages provided. Dietary composition was verified by direct chemical analysis. Blood samples were collected on days 1, 7, 14, 21 and analysed for red blood cell (RBC) membrane fatty acid composition. Pearson correlation showed RBC fatty acid composition to mimic dietary composition by 3 weeks, but the relationships were weak. Of the SFAs only RBC C16:0 decreased in response to decreased dietary content on high-USFA treatment (ANOVA, diet, P < 0.05). Of the USFAs, higher levels of C18:1 MUFA, C20:4 and C22:6 long chain PUFAs on high-USFA diet lead to higher C18:1, C20:4 and C22:6 within RBCs (ANOVA, time*diet, P < 0.05). Pearson’s correlation was significant between dietary and RBC fatty acids during the 21d dietary manipulation for C18:1, and C20:5, C22:6 only (P < 0.05).

Conclusion: RBC membrane fatty acids cannot reliably be used as an independent measure of compliance for dietary SFA intake in short-term studies. The MUFA oleic acid and PUFAs EPA and DHA may be more useful as markers of compliance during short term intervention trials.
Background
Assessment of dietary intake through food records or even weighed food intake is commonly subject to bias, provides only a poor estimate of current and/or habitual diet, and leads to widespread misreporting of energy and nutrient intake [1-7]. Biochemical biomarkers provide reasonable independent assessment tools for some micronutrients [8] but are less widely used for macronutrients such as fatty acids where even qualitative relationships between many important dietary and biological lipids remain to be well demonstrated. One of the major stumbling blocks in assessing the usefulness of fatty acid biomarkers is the use of reported intakes as the comparator in many [9-13] although not all [14-17] validation studies. We were interested in evaluating the use of biomarkers to assess the 3 major classes of fatty acids in subjects whose dietary intake was both fixed and known through provision of all dietary fats during a residential nutrition trial, with a particular interest in determining possible biomarkers of dietary SFA.

The strength of correlation between dietary intake and biomarker appears to vary considerably between individual fatty acids [14]. It would be expected that biomarkers of the ω-3 and ω-6 polyunsaturates (PUFA), such as α-linolenic (ALA, C18:3ω-3) or linoleic acid (LA, C18.2ω-6), would have the strongest association with intake [12,18,19] since the inability to generate double-bonds more than 9 carbons from the carboxyl or delta end of the fatty acid ensure these PUFA may be derived from diet alone. There is some suggestion that SFA with an odd number of carbon atoms, such as pentadecanoic (C15:0) and heptadecanoic acid (C17:0) predominantly from dairy fats, may also provide a good marker of their respective intakes since they can be synthesised only by bacterial flora of ruminants [9,10]. The monounsaturated fats (MUFA) and the SFA with an even number of carbon atoms may be less well correlated with intake [20-26] since their derivation is not dependent on intake from diet alone. Interestingly however a MUFA-enriched diet has been shown to increase circulating MUFA content in several trials [12,15,27], but this finding is not universal.

Table 1: Composition of the two intervention diets as measured by direct chemical analysis

|                     | High SFA       | High USFA      |
|---------------------|----------------|----------------|
| Energy intake, EI (range, MJ/d) | 10.5–15.5    | 10.5–16.0      |
| EI (mean, MJ/d)     | 13.1 ± 0       | 13.2 ± 0.2     |
| CHO, % of energy    | 47 ± 0.6       | 48 ± 0.6       |
| Protein, % of energy| 13 ± 0.7       | 13 ± 0.7       |
| Fat, % of energy    | 40 ± 0.8       | 39 ± 0.8       |
| Cholesterol (mg/d)  | 298 ± 2        | 280 ± 2        |
| Total SFA (calculated, en%) | 20 ± 0.3     | 15 ± 0.3       |
| SFA profile (g/d)   |                |                |
| C10:0 Capric acid   | 2.2 ± 0.2      | 1.7 ± 0.3*     |
| C12:0 Lauric acid   | 8.7 ± 0.9      | 9.7 ± 1.4*     |
| C14:0 Myristic acid | 7.8 ± 0.7      | 5.9 ± 0.6***   |
| C15:0 Pentadecanoic acid | 0.8 ± 0.1 | 0.6 ± 0.1***   |
| C16:0 Palmitic acid | 24.6 ± 1.3     | 17.8 ± 0.8**   |
| C17:0 Heptadecanoic acid | 0.35 ± 0.04 | 0.42 ± 0.03**  |
| C18:0 Stearic acid  | 8.3 ± 0.4      | 11.3 ± 0.4***  |
| Total MUFA (calculated, en%) | 6 ± 0.2      | 8 ± 0.1        |
| MUFA profile (g/d)  |                |                |
| C16:1n-7 Palmitoleic acid | 1.8 ± 1.1   | 0.9 ± 0.8      |
| C18:1n-9 Oleic acid | 21.3 ± 1.7     | 29.5 ± 1.5***  |
| Total PUFA (calculated, en%) | 14 ± 0.1    | 16 ± 0.2       |
| PUFA profile (g/d)  |                |                |
| C18:2n-6 Linoleic acid [LA] | 23.1 ± 1.0   | 30.0 ± 0.9***  |
| C18:3n-3 α-Linolenic acid [ALA] | 1.8 ± 0.3    | 2.4 ± 0.3***   |
| C20:4n-6 Arachidonic acid [AA] | 3.6 ± 0.4    | 4.1 ± 0.4**    |
| C20:5n-3 Eicosapentaenoic acid [EPA] | 0.6 ± 0.1   | 0.6 ± 0.1     |
| C22:4n-6 Docosatetraenoic acid | nd          | nd             |
| C22:6n-3 Docosahexaenoic acid [DHA] | 0.5 ± 0.1    | 0.6 ± 0.1     |

Results are the mean values for 6 duplicate portions. Mean ± sd. SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. Minor fractions of fatty acid profiles not shown. Significantly different from high SFA diet: *P < 0.05, ** P < 0.01, ***P < 0.001, nd, not detectable
There is less evidence of potentially useful SFA biomarkers [12], although a positive relationship has been observed in some studies [29,30].

The purpose of this trial therefore was to measure changes in erythrocyte membrane fatty acids during a period of controlled fat feeding in order to investigate both the rate at which dietary change alters membrane composition to assess potential use as a short-term marker of compliance, and also whether a qualitative biomarker for intake of SFA can be identified when dietary intake is known and rigorously controlled.

Results

Twenty men completed both arms of the intervention. Mean age was 23 (4.1, sd) years, body mass index (BMI) was 21.6 (2.6, sd) kg/m² and all were healthy as assessed by self-report and a biochemical screening panel. The diet was designed to be of typical of western composition, with 40 % of total energy derived from fat, 47% carbohydrate and 13% protein. There was no significant difference between total energy intake or macronutrient composition between treatments (P > 0.05, Table 1) in this cross-over trial. The high-SFA and high-USFA dairy lipids used in the two diets resulted in a significant difference between dietary treatments for all fatty acids measured (paired t-test, P < 0.05; C10:0, C12:0, C14:0, C15:0, C16:0, C17:0, C18:0, C18:1, C18:2, C18:3, C20:4, C22:6, see Table 1) other than C16:1 trans and the n-3 PUFA marine oil eicosapentaenoic acid (EPA, C20:5). The major changes in SFA were in myristic (C14:0, -1.9 g/d, -24%), palmitic (C16:0, -6.8 g/d, -28%) and stearic (C18:0, +3.0 g/d, +36%) acids. The major changes in USFA were in oleic (C18:1, +8.2 g/d, +39%), linoleic (LA, C18:2n-6, +6.9 g/d, +30%), α-linolenic (ALA, C18:3n-3, +0.6 g/d, +33%) and arachidonic (AA, C20:4n-6, +0.5 g/d, +14%) acids.

The erythrocyte fatty acid profile measured on day 21, following 3 weeks of high-SFA and high-USFA treatment are shown in Table 2. There was a significant difference in red blood cell (RBC) fatty acid profile between dietary treatments for C14:0, C16:0, C18:0, C18:1 and C20:4 (paired t-test, P < 0.05). C10:0 and C16:1 could not be detected as individual peaks on the FAME plots on either diet. Throughout the 21 day intervention period, RBC fatty acid profile (Figures 1 & 2, middle and right panels) tended to mimic dietary profile (Figures 1 & 2, left panel) for the majority of fatty acids measured but the relationships were weak.

SFA

Not all individual SFAs were higher on the high-SFA diet, although the design of the trial ensured that total SFA content was higher on this treatment. Dietary C14:0, C15:0 and C16:0 were higher on the high-SFA treatment (P < 0.01), yet RBC analyses showed palmitic acid (C16:0) to be the single SFA which was greater following 21 days of

| Table 2: Erythrocyte fatty acid profile in 20 healthy men following 21 days on a high saturated or a high unsaturated fat diet |
|-----------------------------------------------|
|                                | High SFA (% peak area) | High USFA (% peak area) |
|-----------------------------------------------|
| **SFA profile**                         |
| C10:0 Capric acid                      | nd                     | nd                     |
| C12:0 Lauric acid                      | 0.36 ± 0.22            | 0.39 ± 0.23            |
| C14:0 Myristic acid                    | 0.54 ± 0.07            | 0.49 ± 0.05***         |
| C15:0 Pentadecanoic acid               | 0.20 ± 0.15            | 0.17 ± 0.14            |
| C16:0 Palmitic acid                    | 26.27 ± 0.97           | 25.26 ± 0.89***        |
| C17:0 Heptadecanoic acid               | 0.48 ± 0.12            | 0.50 ± 0.12            |
| C18:0 Stearic acid                     | 9.67 ± 0.91            | 10.31 ± 0.95**         |
| Total SFA                               | 37.5                   | 37.1                   |
| **MUFA profile**                       |
| C16:1n-7 Palmitoleic acid              | nd                     | nd                     |
| C18:1n-9 Oleic acid                    | 10.25 ± 0.82           | 10.70 ± 0.88***        |
| Total MUFA                              | 10.3                   | 10.7                   |
| **PUFA profile**                       |
| C18:2n-6 Linoleic acid [LA]            | 15.25 ± 1.65           | 14.99 ± 1.77           |
| C18:3n-3 α-Linolenic acid [ALA]        | 0.4 ± 0.2              | 0.4 ± 0.2              |
| C20:4n-6 Arachidonic acid [AA]         | 10.17 ± 1.01           | 10.6 ± 0.88***         |
| C20:5n-3 Eicosapentaenoic acid [EPA]   | 0.62 ± 0.13            | 0.56 ± 0.24            |
| C22:4n-6 Docosatetraenoic acid         | 1.90 ± 0.42            | 1.99 ± 0.58            |
| C22:6n-3 Docosahexaenoic acid [DHA]    | 2.77 ± 0.51            | 2.82 ± 0.53            |
| Total PUFA                              | 27.7                   | 31.4                   |

SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. % peak area calculated from fatty acid methyl esters (FAMEs). Minor fractions of fatty acid profiles not shown. Significantly different from high SFA diet: *P < 0.05, ** P < 0.01, ***P < 0.001, nd, not detectable. Mean ± sd
Dietary (left panel) and red blood cell (RBC, centre and right panels) saturated fatty acid composition during the 3 week high-saturated (high-SFA) and high-unsaturated (high-USFA) dietary treatments. Diet was strictly controlled by providing subjects with all food and drinks throughout the 6 week residential intervention. Treatments were separated by a minimum 4 week wash-out period. Change in RBC membrane fatty acids was measured on day 1, d7, d14 and d21 of each intervention arm (● high-SFA, ○ high-USFA). AUC day 1–21, area under the curve of change in RBC % peak area.
Figure 2
Dietary (left panel) and red blood cell (RBC, centre and right panels) mono- and polyunsaturated fatty acid composition during the 3 week high-saturated (high-SFA) and high-unsaturated (high-USFA) dietary treatments. Diet was strictly controlled by providing subjects with all food and drinks throughout the 6 week residential intervention. Treatments were separated by a minimum 4 week wash-out period. Change in RBC membrane fatty acids was measured on day 1, d7, d14 and d21 of each intervention arm (● high-SFA, ○ high-USFA). AUC day 1–21, area under the curve of change in RBC % peak area.
the high-SFA diet compared with 21 days of high-USFA treatment (Figure 1, ANOVA, diet*time, P < 0.05). In contrast, dietary C12:0, C17:0 and C18:0 were all lower on the high-SFA treatment (P < 0.05), but RBC analyses showed stearic acid (C18:0) to be the single SFA significantly lower on the high-SFA relative to high-USFA treatment (ANOVA, diet*time, P < 0.05). With the exception of C16:0 there were significant increases above baseline RBC values in response to both treatments in all RBC SFAs over the 21 day intervention, possibly due to the change from habitual home diet (ANOVA, time, P < 0.01). RBC palmitic acid decreased on both treatments over time (ANOVA, time, P < 0.001).

MUFA
Dietary oleic acid (C18:1) content was significantly higher on the high-USFA treatment (Figure 2, left panel, P < 0.001), which induced a significantly greater RBC oleic acid content over 21 days compared to high-SFA diet (Figure 2, middle and right panels, ANOVA, diet*time, P < 0.05). Both diets caused a decrease in RBC C18:1 content between baseline and follow-up which was independent of treatment group (ANOVA, time, P < 0.001).

PUFA
Dietary linoleic (LA, C18:2), α-linolenic (ALA, C18:3), arachidonic (AA, C20:4) and docosahexaenoic acid (DHA, C22:6) were all significantly greater on the high-USFA treatment (Figure 2, left panel, P < 0.001), which induced a significantly greater RBC oleic acid content over 21 days compared to high-SFA diet (Figure 2, middle and right panels, ANOVA, diet*time, P < 0.05). Both diets caused a decrease in RBC C18:1 content between baseline and follow-up which was independent of treatment group (ANOVA, time, P < 0.001).

Discussion
This trial was designed to assess whether red blood cell fatty acids can provide a qualitative short term, independent measure of dietary lipid intake. We were particularly interested in the saturated fatty acids since a high intake has been repeatedly shown to be closely linked to numerous disease states in dietary trials, yet independent markers of intake are not as yet available. There were a number of important features of this trial. Firstly that dietary lipid intake was carefully measured and rigorously controlled throughout the intervention by provision of foods in a residential setting. The disadvantage of such a protocol

| Table 3: Pearson correlations between diet and RBC fatty acid composition for the 2 dietary treatments (r values) |
|---------------------------------------------------------------|
| Fatty acid | day 1 | day 7 | day 14 | day 21 | day 1 | day 7 | day 14 | day 21 |
| SFA        |
| C12:0      | 0.251 | 0.161 | 0.101 | 0.141 | 0.100 | 0.140 | 0.040 | 0.001 |
| C14:0      | 0.497* | 0.231 | 0.179 | 0.075 | 0.248 | 0.330 | 0.163 | 0.145 |
| C15:0      | 0.180 | 0.390* | 0.121 | 0.265 | 0.336 | 0.106 | 0.036 | 0.026 |
| C16:0      | 0.143 | 0.169 | 0.134 | 0.193 | 0.356 | 0.238 | 0.054 | 0.251 |
| C17:0      | 0.229 | 0.062 | 0.200 | 0.226 | 0.391* | 0.101 | 0.053 | 0.061 |
| C18:0      | 0.200 | 0.101 | 0.339 | 0.124 | 0.213 | 0.351 | 0.379* | 0.326 |
| MUFA       |
| C18:1      | 0.386* | 0.157 | 0.412* | 0.226 | 0.008 | 0.218 | 0.336 | 0.421* |
| PUFA       |
| C18:2      | 0.315 | 0.319 | 0.509* | 0.223 | 0.237 | 0.278 | 0.260 | 0.304 |
| C18:3      | 0.262 | 0.143 | 0.313 | 0.218 | 0.028 | 0.169 | 0.121 | 0.155 |
| C20:4      | 0.078 | 0.114 | 0.144 | 0.038 | 0.014 | 0.191 | 0.202 | 0.130 |
| C20:5      | 0.197 | 0.419* | 0.473* | 0.487* | 0.257 | 0.223 | 0.243 | 0.167 |
| C22:6      | 0.373* | 0.447* | 0.433* | 0.369* | 0.408* | 0.480* | 0.491* | 0.394* |

SFA, saturated fatty acid; USFA, unsaturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; *P < 0.05
however is that the rigorous nature of the intervention necessarily minimises the length of the trial. It has been well demonstrated that favourable alterations in diet can result in favourable alterations in serum lipids and lipoproteins over periods as short as 2–3 weeks [31,32], and that efficacy of putative lipid lowering dietary therapies following stabilisation of serum lipid endpoints can be established within 21 days [31-34]. It was on the basis of this information that we established the protocol for this trial and were interested to establish useful short-term serum lipid markers.

Our current trial showed that even on a diet containing as much as 15–20 % of energy as SFAs, RBC fatty acid biomarkers provide a very poor estimate of intake. As per the trial design, with the exception of the marine oil EPA, all measured dietary fatty acids altered in response to the inclusion of the high-SFA and high-USFA dairy lipid into the diet. The change in RBC profile in response to these dietary changes was significant in 5 of the 12 measured fatty acids, palmitic (C16:0), stearic (C18:0), oleic (C18:1), AA (C20:4) and DHA (C22:6), of which only the MUFA oleic acid and the LCPUFA DHA were significantly correlated with diet on the final day of the intervention, day 21. Despite significant differences in dietary content of both SFAs C15:0 and C17:0 there was no evidence in this relative short-term trial that RBC fatty acids can be used as a reliable biomarker for intake.

In an observational study of 62 older men Smedman and colleagues [9] have previously shown total C15:0 content of serum cholesterol esters (CE) and phospholipids to be a reasonable marker for longterm intake of milk lipids, estimated using 7 day food records. Wolk and co-workers [10] also found a significant correlation between CE and phospholipids C15:0 and habitual diet assessed more rigorously by 2 weighed food records and fourteen 24-h diet recall interviews over a period of 12 months. Alternately, a group working in Japan presumably on a relatively low-dairy high-fish consuming population, were unable to find any relationship between dietary and serum phospholipid SFAs in an observational trial of 87 men [12]. None of these trials addressed the issue of compliance to changes during intervention protocols. Zock [14] had earlier reported that analysis of a combination of different intervention trials carried out in their laboratory in the Netherlands, every 10% of energy fed as a mixture of SFA lead to an increase in serum CE fatty acid content of 2.2 g/100 g, and that this was slightly lower for palmitic (1.7 g/100 g) and myristic (2.1 g/100 g) acid. This compared badly with changes of 9.3 g/100 g for the n6 PUFA linoleic acid and 6.5 g/100 g for the MUFA oleic acid. Whilst the effect of dietary change on RBC fatty acids may be less pronounced than that in plasma, it has been shown to produce a less variable result [16], which is why it was chosen for analysis in this validation trial.

**Conclusion**

In conclusion, we were unable to show a significant correlation between dietary and RBC levels of any saturated fatty acids in this 3 week, carefully controlled intervention trial and hence cannot support the use of RBC SFA levels as a reliable biomarker for intake of dietary SFA [9,10]. Despite a number of potential origins for RBC MUFA in addition to dietary intake, oleic acid (C18:1) was correlated with diet when there was a high content of USFA. It was clear that the LCPUFA DHA showed the strongest correlation between diet and RBC levels on all dietary treatments and at all time points, even in this relatively short-term intervention, confirming its potential as a reliable biomarker in trials manipulating marine oils.

**Methods Subjects**

Twenty lean male volunteer subjects were recruited into the study following newspaper advertisements. All subjects were self-motivated to take part in the study, agreed to maintain the strict regime of dietary control and residence within the metabolic facility. Subjects were healthy with no evidence of metabolic or endocrine disorders. All participants underwent a biochemical screening panel to ensure good health and completed a brief medical history. Ethics approval for this study was obtained from the Auckland Ethics Committee, Auckland, New Zealand and subjects provided written informed consent.

**Protocol**

This study was a double-blind, randomised, cross-over intervention in which a high-saturated fatty acid (high-SFA, 20 en%) and a high-unsaturated fatty acid (high-USFA, 24 en%) diet was given to subjects over two periods of 3 weeks. Subjects were required to be resident at the University of Auckland Human Nutrition Unit throughout both dietary intervention periods. All foods and beverages were provided during the interventions and participants were asked to eat no other foods and to abstain from drinking alcohol. This ensured that the fatty acid profile of the diet was controlled and known. The two intervention periods were 21 days in length and separated by a minimum washout period of 4 weeks during which time the volunteers returned home and resumed their normal diet. Blood samples were routinely collected throughout the intervention to measure the fatty acid composition of the erythrocyte membrane. Blood samples were collected by venipuncture on the morning of day 1 (pre-intervention baseline), 7, 14 and 21 of each intervention period following a 12 hour fast. Duplicate diet portions were prepared throughout the trial and fro-
zen for later direct measurement of fatty acid composition.

**Dietary intake**

Diet was controlled on both intervention arms by providing participants with all of their dietary requirements. The intention was to ensure that only trial foods were eaten and thereby firmly establish the fatty acid profile of the diet throughout each 3 week period. Participants were asked to eat all foods provided for them and each diet was designed on an individual basis to maintain energy balance through a combination of calculations based on multiples of predicted basal metabolic rate (BMR), daily assessment of body weight and discussion of hunger and satiety levels between participants and the research team. A 4 day dietary rotation was used during the study such that every 5th day the entire diet repeated over the 21 days. Subjects were provided with breakfast, lunch, dinner and between-meal snacks. Breakfast and dinner were eaten under supervision at the Nutrition Unit, whilst lunch and snacks were packed and volunteers were able to take them to college or their place as work as required. Decaffeinated, sugar-free beverages and decaffeinated tea and coffee were freely available. The 2 diets comprised 40 energy % (en %) fat, 47 en % CHO and 13 en % protein but differed considerably in their fatty acid composition (Table 1). The alteration in fatty acids was made through the inclusion of a high-SFA or a high-USFA dairy lipid into the diet, details of which are given in a previous publication [35]. The butter fat provided half of the total fat in the diet (20% of total energy), scaled to total energy intake and body weight for each individual. The energy and macronutrient content of the diet were verified by direct chemical analyses of duplicate diet samples. On 12 occasions during the intervention a duplicate 4 day diet from a single subject was collected, homogenised and an aliquot frozen for later chemical analysis. This enabled the absolute composition of the diet to be verified.

**Blood samples**

Venous blood samples were collected into EDTA vacutainers and centrifuged immediately after collection at 3000 rpm for 15 minutes. Supernatant plasma was then removed. Erythrocytes were washed and transferred into a -80°C freezer for long-term storage until analysed. The erythrocyte membrane lipid extraction was based on the method of Rose and Oklander [36] and used the solid-phase extraction technique of Kaluzny et al [37]. Frozen, buffer-washed, packed erythrocytes were thawed at room temperature and lysed under vortex with purified Milli-Q water. A chemical preservative of iso-propanol containing 0.005% butylated hydroxytoluene was slowly added to the cells, under vortex to prevent RBCs caking into a solid plug, as an anti-oxidant for the PUFAs. Chloroform was then added with constant vortex mixing and the samples allowed to stand for 1 hour. The samples were then centrifuged at 500 g and the liquid phase containing the erythrocyte membrane lipids removed and evaporated under an oxygen-free nitrogen stream to concentrate the total lipid fraction. A three-step solid phase extraction procedure using extract-clean NH$_2$ extraction cartridges (Alltech, Tennessee, US) on a vacuum manifold was then used to separate the lipid fractions into neutral lipids, fatty acids, and phospholipid sub-fractions. The phospholipid portions were methylated through addition of boron trifluoride in methanol (~14% BF3), N$_2$ flushing and heating to 70°C to form fatty acid methyl esters (FAMEs). Samples were quantitatively analysed on a gas chromatograph equipped with an auto injector (Hewlett Packard™ 5890 Series II, Palo Alto, US). Conditions included 0.25 mm ID, 0.15 µm film thickness J&W DB-225 column; injection volume 5 µl; injector 240°C; detector 250°C; oven temperature program 80°C initially ramping to 135°C at 70°C/min after injection and then slowing to 3°C/min. Blood samples for each individual subject were processed in parallel to ensure that minor variations in sample handling were minimised.

**Statistical analyses**

All data was analysed using GraphPad Prism version 4.03 for Windows, (GraphPad Software, San Diego, California, USA). Paired t-tests were carried out for between-treatment comparison of diet, including energy intake, macronutrient and fatty acid composition, and between-treatment comparison of erythrocyte fatty acid profile at day 21. Two-way ANOVA was performed to analyse change in RBC fatty acid composition over time between baseline on day 1 and the end of the intervention on day 21 for both dietary treatments. Pearson correlations between dietary and RBC fatty acids were performed on day 1, d7, d14 and d21 of the intervention. Statistical significance was based on 95% confidence limits (P < 0.05).

**List of Abbreviations Used**

- ALA Alpha-linolenic acid
- ANOVA Analysis of variance
- AA Arachidonic acid
- BMI Body mass index
- BMR Basal metabolic rate
- CE Cholesterol Ester
- DHA Docosahexaenoic acid
- EDTA Ethylenediaminetetraacetic acid

---

**Page 8 of 10**

(page number not for citation purposes)
4. Poppitt SD, Swann DL, Black AE, Prentice AM: Acknowledgements

Thanks must also go to the participants who were resident at the University of Auckland Human Nutrition Unit. Cynthia Tse provided laboratory and administrative support. Tracey Petley-Hibbs and Truusje Broekhoff for their assistance during study for this trial. We are grateful to Jenneke van Drunen, Esther de Swart, Martin was co-principal investigator and responsible for author and fund raiser. Responsible for clinical trial subject recruitment and screening, subject trial supervision. Dr P Kil马丁 was co-principal investigator and responsible for the laboratory protocol design, method development and supervision of technical staff. P Butler was the senior laboratory technician. Responsible for methodological work up and red blood cell and dietary fatty acid analyses. GF Keogh was the trial manager responsible for subject recruitment and screening, subject trial supervision, diet design, phlebotomy, sample collection & storage.

Acknowledgements

We thank Glyn Muir who provided kitchen management and diet preparation for this trial. We are grateful to Jenneke van Drunen, Esther de Swart, Tracey Petley-Hibbs and Truusje Broekhoff for their assistance during studentships. Cynthia Tse provided laboratory and administrative support. Thanks must also go to the participants who were resident at the University of Auckland Human Nutrition Unit.

References

1. Prentice AM, Black AE, Coward WA, Davies HL, Goldberg GR, Murgatroyd PR, Ashford J, Sawyer M: High levels of energy expenditure in obese women. Br Med J 1996, 292:983-987.
2. Lichtman SW, Pisarska K, Berman ER, Pestone M, Dowling H, Offenbacher E, Weisel H, Heshka S, Matthews DE, Heymsfield SB: Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med 1992, 327:1893-1898.
3. Bingham SA, Cassidy A, Cole TJ, Welch AA, Runswick SA, Black AE, Thornham D, Bates CJ, Khaw KT, Key TJ, Day NE: Validation of weighed records and other methods of dietary assessment using the 24h urine nitrogen technique and other biological markers. Br J Nutr 1995, 73:531-550.
4. Poppitt SD, Swann DL, Black AE, Prentice AM: Assessment of selective under-reporting of food intake by both obese and non-obese women in a metabolic facility. Int J Obesity 1998, 22:303-311.
5. Goris AHC, Westerterp-Plantenga MS, Westerterp KR: Underestimating and underreporting of habitual food intake in obese men: selective underreporting of fat intake. Am J Clin Nutr 2000, 71:130-134.
6. Black AE, Cole TJ: Biased over- or under-reporting is characteristic of individuals whether over time or different assessment methods. J Am Diet Assoc 2001, 101:70-80.
7. Poppitt SD: Underreporting in overweight subjects - is protein well reported? Prog Obesity Res 2003, 9:508-518.
8. McKeown NM, Day NE, Welch AA, Runswick SA, Luben RN, Mulligan AA, McTaggart A, Bingham SA: Use of biological markers to validate self-reported dietary intake in a random sample of the European Prospective Investigation into Cancer, United Kingdom Norfolk cohort. Am J Clin Nutr 2001, 74:188-196.
9. Smedman AE, Gustafsson IB, Berglund LG, Vessby Bo: Pentadecenoic acid in serum as a marker for intake of milk fat: relations between intake of milk fat and metabolic risk factors. Am J Clin Nutr 1999, 69:22-29.
10. Wolk A, Furuheim M, Vessby Bo: Fatty acid composition of adipose tissue and serum lipids are valid biological markers of dietary fat intake in men. J Nutr 2001, 131:828-833.
11. Salmeron J, Hu FB, Manson J, Stampfer MJ, Colditz GA, Rimm EB, Willett WC: Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 2001, 73:1019-1026.
12. Kobayashi M, Sasaki S, Kawabata K, Akabane M, Tsugane S: Single measurement of serum phospholipid fatty acid as a biomarker of specific fatty acid intake in middle aged Japanese men. Eur J Clin Nutr 2001, 55:643-650.
13. Niskani T, Luukkanen P, Pietinen P, Puspa P: Fatty acid composition of serum lipids in relation to gender and quality of dietary fat. Am J Clin Nutr 1995, 62:491-496.
14. Zock PL, Mensink RP, Haryan J, de Vries JH, Kanat MB: Fatty acids in serum cholesteryl esters as quantitative biomarkers of dietary intake in humans. Am J Epidemiol 1997, 145:1114-1122.
15. Pagnan A, Carrocher R, Ambrosio GB, Ferrari S, Guarini P, Piccolo D, Opportuno A, Bassi A, OLivieri O, Baggi B: Effects of an olive-oil-rich diet on erythrocyte membrane lipid composition and cation transport systems. Clin Sci 1989, 76:87-93.
16. Glatz JF, Soferes AE, Kanat MB: Fatty acid composition of serum cholesteryl esters and erythrocyte membranes as indicators of linoleic acid intake in man. Am J Clin Nutr 1989, 49:269-276.
17. Ruiz-Gutierrez V, Muriana FJ, Guererro A, Cert AM, Villar J: Plasma lipids, erythrocyte membrane lipids and blood pressure of hypertensive women after ingestion of dietary oleic acid from two different sources. J Hypertens 1996, 14:1483-1490.
18. Andersen LF, Solvoll K, Drenov CA: Very-long-chain n-3 fatty acids as biomarkers for intake of fish and n-3 fatty acid concentrates. Am J Clin Nutr 1996, 64:305-311.
19. Leaf DA, Connor WE, Barstad L, Sexton G: Incorporation of dietary n-3 fatty acids into the fatty acids of human adipose tissue and plasma lipids classes. Am J Clin Nutr 1995, 62:687-693.
20. Beynen AC: The role of specific fatty acid intake in middle aged Japanese men. Am J Clin Nutr 1995, 62:491-496.
21. Hunter DJBRSEMMICOLLARJWVWC: Comparison of measures of fatty acid intake by subcutaneous fat aspirate, food frequency questionnaire, and diet records in a free-living population of US men. Am J Epidemiol 1992, 135:418-427.
22. Ma J, Folsom AR, Shaker E, Eckfeldt JH: Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Clin Nutr 1995, 62:564-571.
23. Sarkkinen ES, Agren J, Ahola I, Ovaskainen ML, Uusitupa MI: Serum fatty acid composition of cholesterol esters, and erythrocyte and platelet membranes as indicators of long term adherence to fat-modified diets. Am J Clin Nutr 1994, 59:364-370.
24. vanStaveren WA, Deurenberg P, Katan MB, Durema J, Groot LC, Hoffmans MM: Validity of the fatty acid composition of subcutaneous adipose tissue in a population of healthy non-obese men. Am J Clin Nutr 1986, 34:269-276.
26. Tjonneland A, Overvad K, Thorling E, Ewertz M: Adipose tissue fatty acids as biomarkers of dietary exposure in Danish men and women. Am J Clin Nutr 1993, 57:629-633.

27. Corrocher R, Pagani A, Ambrosio GB, Ferrarri S, Olivieri O, Guarini P, Bassi A, Piccolo D, Gandini A, Girelli D: Effects induced by olive oil-rich diet on erythrocytes membrane lipids and sodium-potassium transports in postmenopausal hypertensive women. J Endocrinol Invest 1992, 15:369-376.

28. Wang L, Folsom AR, Zheng ZJ, Pankow JS, Eckfeldt JH, Investigators ARIC: Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 2003, 78:91-98.

29. Tholstrup T, Marcckmann P, Jespersen J, Yessby B, Jart A, Sandstrom B: Effect on blood lipids, coagulation and fibrinolysis of a fat high in myristic acid and a fat high in palmitic acid. Am J Clin Nutr 1994, 60:919-925.

30. Kelly FD, Sinclair AJ, Mann NJ, Turner AH, Abedin L, Li D: A stearic acid-rich diet improves thrombogenic and atherogenic risk factor profiles in healthy males. Eur J Clin Nutr 2001, 55:88-96.

31. Mensink RP, Katan MB: Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 1992, 12:911-919.

32. Fumeron F, Brignon L, Parra HJ, Bard JM, Fruchart JC, Apfelbaum M: Lowering of HDL2-cholesterol and lipoprotein A-1 particle levels by increasing the ratio of polyunsaturated to saturated fatty acids. Am J Clin Nutr 1991, 53:655-659.

33. Kris-Etherton PM, Dietschy JM: Design criteria for studies examining individual fatty acid effects on cardiovascular disease: human and animal studies. Am J Clin Nutr 1997, 65:1590S-1596S.

34. Hodson L, Skeaff CM, McKenzie JE: Maximal response to a plasma cholesterol-lowering diet is achieved within two weeks. Nutr metab Cardiovasc Dis 2002, 12:291-295.

35. Poppitt SD, Keogh GF, Mulvey TB, McArdle BH, MacGibbon AK, Cooper GJ: Lipid-lowering effects of a modified butter fat: a controlled intervention trial in healthy men. Am J Clin Nutr 2002, 56:64-71.

36. Rose HG, Oklander M: Improved procedure for the extraction of lipids from human erythrocytes. J Lipid Res 1965, 6:428-431.

37. Kaluzny MA, Duncan LA, Merritt MV, Epps DE: Rapid separation of lipid classes in high yield and purity using bonded phase columns. J Lipid Res 1985, 26:135-140.